document
human
infect
middl
east
respiratori
syndrom
coronaviru
merscov
case
fatal
rate
approxim
medic
countermeasur
need
prevent
limit
diseas
examin
vivo
efficaci
human
monoclon
antibodi
high
neutral
activ
merscov
vitro
administ
rabbit
intraven
intranas
infect
merscov
prophylaxi
result
reduct
pulmonari
viral
rna
titer
compar
irrelev
control
antibodi
littl
inflamm
viral
antigen
detect
protect
rabbit
support
clinic
develop
keyword
merscov
prophylaxi
rabbit
human
mab
middl
east
respiratori
syndrom
coronaviru
merscov
first
detect
human
februari
confirm
infect
associ
death
global
diseas
sever
appear
vari
basi
comorbid
age
infect
individu
sever
infect
merscov
result
acut
respiratori
distress
syndrom
renal
failur
death
younger
patient
without
preexist
condit
typic
display
milder
diseas
humantohuman
transmiss
merscov
identifi
sever
occas
transmiss
chain
selflimit
natur
occur
predominantli
hospit
set
howev
notabl
larg
outbreak
occur
south
korea
spread
one
infect
travel
result
case
death
human
infect
sporad
repeat
reintroduct
anim
reservoir
middl
east
suggest
outbreak
continu
sever
anim
model
develop
merscov
brief
nonhuman
primat
explor
rhesu
macaqu
display
mild
infect
marmoset
display
sever
diseas
mice
natur
suscept
experiment
infect
merscov
sever
model
gener
express
human
dipeptidyl
peptidas
receptor
new
zealand
white
rabbit
also
experiment
infect
merscov
result
asymptomat
infect
may
repres
mild
human
diseas
rabbit
natur
display
molecul
allow
attach
infect
merscov
infect
lead
pulmonari
diseas
character
mild
perivascular
peribronchiolar
inflamm
viral
titer
peak
day
inocul
merscov
infect
rabbit
model
monitor
patholog
analysi
viral
replic
evalu
model
test
potenti
medic
countermeasur
although
human
mer
infect
document
sinc
approv
mersspecif
vaccin
antivir
therapeut
yet
avail
sever
vaccin
candid
develop
limit
number
treatment
option
test
vivo
monoclon
antibodi
convalesc
sera
evalu
mice
two
recent
report
monoclon
antibodi
result
reduct
viru
titer
follow
administr
transgen
mous
model
human
monoclon
antibodi
hmab
isol
larg
phagedisplay
librari
interact
receptorbind
domain
merscov
spike
protein
show
except
potent
neutral
activ
merscov
vitro
evalu
vivo
efficaci
use
rabbit
model
merscov
isol
erasmu
medic
center
netherland
grown
cell
optimem
gibco
plu
fetal
bovin
serum
hyclon
store
tissu
cultur
infect
dose
tcid
per
millilit
determin
cell
calcul
use
reedmuench
method
femal
new
zealand
white
rabbit
covanc
princeton
new
jersey
age
month
anesthet
intramuscular
dexmedetomidin
inhal
isofluran
sedat
revers
subcutan
administr
atipamezol
rabbit
infect
intranas
ml
tcid
gibco
serum
sampl
collect
day
antibodi
administr
necropsi
anim
euthan
day
infect
lung
tissu
collect
anim
studi
conduct
biosafeti
level
laboratori
nation
institut
health
nih
protocol
approv
nih
anim
care
use
committe
antibodi
gener
previous
describ
rabbit
given
ml
mgkg
mgkg
intraven
intranas
respect
prophylaxi
treatment
studi
day
day
merscov
infect
rabbit
control
group
given
mgkg
irrelev
control
hmab
specif
hendra
viru
lung
tissu
store
process
tissu
homogen
contain
antibioticantimycot
invitrogen
final
wtvol
centrifug
minut
rpm
swing
bucket
rotor
sorval
viral
rna
isol
use
qiamp
viral
rna
mini
kit
qiagen
qrtpcr
analysi
run
duplic
use
ng
rna
per
reaction
merscov
nucleoprotein
primer
superscript
iii
platinum
onestep
qrtpcr
kit
life
technolog
sampl
run
serial
dilut
viru
stock
viral
titer
express
log
tcid
equivalentsgram
tissu
statist
signific
determin
use
analysi
varianc
tukey
multipl
comparison
test
lung
tissu
sampl
lobe
resect
formalinfix
tissu
tissu
embed
paraffin
divid
section
stain
hematoxylin
eosin
histoserv
germantown
maryland
section
examin
light
microscopi
use
olympu
microscop
photomicrograph
taken
use
olympu
camera
lung
section
bake
hour
deparaffin
xylen
rehydr
alcoholgrad
wash
section
microwav
antigen
unmask
solut
vector
laboratori
exposur
protein
block
dako
minut
mous
antim
nucleocapsid
antibodi
biorbyt
ad
dilut
follow
biotinyl
hors
antimous
immunoglobulin
g
igg
vector
laboratori
dilut
section
incub
minut
vectastain
abcap
reagent
vector
laboratori
minut
vulcan
fast
red
chromogen
biocar
medic
counterstain
hematoxylin
serial
dilut
rabbit
sera
prepar
equal
volum
viru
sera
combin
incub
hour
room
temperatur
mixtur
ad
quadrupl
cell
neutral
titer
reciproc
highest
serum
dilut
neutral
infect
tcid
viru
read
absenc
cytopath
effect
day
infect
hmab
administ
rabbit
intraven
mgkg
mgkg
addit
rabbit
receiv
hendra
virusspecif
hmab
isotyp
control
one
day
later
rabbit
infect
intranas
tcid
merscov
reduct
viral
rna
titer
observ
day
infect
rabbit
receiv
mgkg
mgkg
respect
compar
control
group
figur
reduct
viral
rna
titer
signific
group
day
infect
reduct
neutral
mersspecif
antibodi
titer
sera
rabbit
receiv
mgkg
rang
immedi
infect
remain
rang
day
infect
supplementari
tabl
group
receiv
mgkg
serum
titer
rang
viru
inocul
day
infect
control
group
rabbit
develop
detect
neutral
antibodi
rabbit
administ
control
antibodi
intraven
show
mild
perivascular
peribronchiolar
lesser
extent
alveolar
interstiti
inflamm
character
predominantli
eosinophil
histiocyt
infiltr
figur
ihc
evalu
reveal
merscov
antigen
distribut
perivascular
peribronchiolar
pattern
supplementari
figur
rabbit
receiv
either
dose
evid
inflamm
viru
antigen
figur
supplementari
figur
test
altern
rout
antibodi
administr
hmab
also
administ
rabbit
intranas
one
day
later
rabbit
infect
intranas
within
day
rabbit
receiv
mgkg
reduct
rabbit
receiv
mgkg
reduct
viral
rna
titer
compar
control
figur
day
infect
major
rabbit
clear
merscov
rna
merscovspecif
neutral
antibodi
detect
sera
rabbit
follow
intranas
administr
data
shown
rabbit
receiv
control
antibodi
intranas
show
mild
perivascular
peribronchiolar
inflamm
character
mixtur
eosinophil
histiocyt
figur
ihc
evalu
reveal
merscov
antigen
often
distribut
perivascular
peribronchiolar
pattern
lesser
extent
within
alveolar
interstitium
supplementari
figur
rabbit
receiv
either
dose
minim
inflamm
evid
viru
antigen
figur
supplementari
figur
establish
preexposur
prophylaxi
highli
effect
sought
assess
use
postexposur
treatment
merscovinfect
rabbit
antibodi
administ
rabbit
intraven
intranas
day
infect
lung
tissu
collect
day
infect
serum
neutral
antibodi
titer
detect
day
follow
administr
rang
mgkg
group
mgkg
group
similar
titer
necropsi
supplementari
tabl
similar
observ
prophylaxi
studi
neutral
antibodi
detect
sera
rabbit
receiv
antibodi
intranas
data
shown
although
serum
neutral
antibodi
titer
achiev
treatment
studi
compar
found
prophylaxi
studi
antibodi
treatment
intraven
intranas
rout
effect
reduc
viral
rna
titer
supplementari
figur
b
rabbit
receiv
either
hmab
follow
infect
show
similar
histolog
chang
lung
character
mild
perivascular
peribronchiolar
accumul
eosinophil
histiocyt
supplementari
figur
addit
distribut
viru
antigen
found
close
proxim
blood
vessel
small
airway
rabbit
neutral
monoclon
antibodi
proven
use
treatment
sever
viral
infect
human
also
demonstr
effect
anim
model
sarscov
studi
found
prophylaxi
figur
viral
titer
rabbit
lung
follow
intraven
prophylaxi
neutral
monoclon
antibodi
rabbit
receiv
middl
east
respiratori
syndrom
coronaviru
merscov
specif
human
monoclon
antibodi
hmab
irrelev
control
hmab
intraven
hour
intranas
infect
tissu
cultur
infect
dose
tcid
lung
collect
day
infect
viral
titer
quantifi
quantit
real
time
polymeras
chain
reaction
analysi
b
c
imag
hematoxylineosinstain
section
rabbit
treat
control
antibodi
b
mgkg
c
data
rabbit
per
group
arrowhead
inset
highlight
area
intens
perivascular
inflamm
imag
taken
day
infect
origin
magnif
inset
origin
magnif
black
bar
equival
imag
origin
magnif
p
p
analysi
varianc
tukey
multipl
comparison
test
abbrevi
eq
equival
hmab
result
signific
reduct
viral
rna
titer
virusrel
patholog
lung
rabbit
although
low
amount
viral
rna
detect
rabbit
figur
almost
viral
antigen
identifi
ihc
analysi
indic
infect
lower
respiratori
tract
prevent
intraven
administr
result
neutral
antibodi
titer
serum
sever
day
supplementari
tabl
intranas
administr
antibodi
result
detect
titer
impli
topic
administ
antibodi
remain
respiratori
tract
could
account
greater
efficaci
antibodi
administ
intranas
versu
intraven
merscovinfect
rabbit
develop
diseas
may
repres
mild
asymptomat
human
infect
observ
somewhat
sever
lung
inflamm
previous
report
like
due
differ
rout
volum
viru
administr
inflamm
present
area
lung
antibodi
administ
intranas
compar
intraven
although
sever
compar
supplementari
tabl
could
result
addit
volum
deliv
intranas
achiev
dose
mgkg
howev
sinc
mgkg
treatment
effect
larg
inoculum
volum
requir
futur
studi
postinfect
therapi
hmab
either
rout
result
reduct
viral
rna
titer
measur
qrtpcr
possibl
high
viral
inoculum
infect
suscept
cell
respiratori
tract
administr
hmab
could
prevent
replic
viru
alreadi
infect
cell
altern
qrtpcr
measur
viabl
nonviabl
viral
particl
measur
may
accur
reflect
infecti
viru
recent
data
mab
support
notion
foldreduct
titer
infecti
viru
antibodi
treatment
greater
reduct
viral
rna
level
therefor
evalu
potenti
therapi
requir
studi
effect
infecti
viru
hmab
high
specif
neutral
activ
merscov
vitro
demonstr
vivo
efficaci
rabbit
signific
reduct
viral
rna
titer
figur
viral
titer
rabbit
lung
follow
intranas
prophylaxi
neutral
monoclon
antibodi
rabbit
receiv
middl
east
respiratori
syndrom
coronaviru
merscov
specif
human
monoclon
antibodi
hmab
irrelev
control
hmab
intranas
hour
intranas
infect
tissu
cultur
infect
dose
tcid
lung
collect
day
infect
viral
titer
quantifi
quantit
real
time
polymeras
chain
reaction
analysi
b
c
imag
hematoxylineosinstain
section
rabbit
treat
control
antibodi
b
mgkg
c
data
rabbit
per
group
arrowhead
inset
highlight
area
intens
perivascular
inflamm
imag
taken
day
infect
origin
magnif
inset
origin
magnif
black
bar
equival
p
p
analysi
varianc
tukey
multipl
comparison
test
abbrevi
eq
equival
demonstr
lung
follow
prophylaxi
rout
within
day
infect
observ
reduct
pulmonari
viral
rna
load
minim
inflamm
viral
antigen
present
result
indic
antibodi
administ
exposur
abl
prevent
merscov
infect
warrant
develop
medic
countermeasur
merscov
infect
supplementari
materi
avail
http
jidoxfordjournalsorg
consist
data
provid
author
benefit
reader
post
materi
copyedit
sole
respons
author
question
comment
address
author
